

(19)

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 495 878 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
27.11.1996 Bulletin 1996/48

(21) Application number: 90915696.0

(22) Date of filing: 10.10.1990

(51) Int. Cl.⁶: A61K 51/04, G01N 33/532,
G01N 33/533, G01N 33/534

(86) International application number:
PCT/US90/05772

(87) International publication number:
WO 91/06008 (02.05.1991 Gazette 1991/10)

(54) METHOD FOR PURIFYING CHELATOR CONJUGATED COMPOUNDS

VERFAHREN ZUR REINIGUNG VON CHELATOR-KONJUGIERTEN VERBINDUNGEN
PROCEDE DE PURIFICATION DE COMPOSES CONJUGUES CHELATEURS

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

(30) Priority: 11.10.1989 US 419871

(43) Date of publication of application:
29.07.1992 Bulletin 1992/31

(73) Proprietors:
• Akzo Nobel N.V.
6824 BM Arnhem (NL)
• Subramanian, Ramaswamy
Frederick, MD 21701 (US)

(72) Inventor: SUBRAMANIAN, Ramaswamy
Frederick, MD 21701 (US)

(74) Representative: Hermans, Franciscus G.M. et al
P.O. Box 20
5340 BH Oss (NL)

(56) References cited:

- EP-A- 0 264 333 FR-A- 2 527 928
US-A- 4 283 382 US-A- 4 652 440
- JOURNAL OF NUCLEAR MEDICINE. vol. 28, no. 5, May 1987, NEW YORK US pages 861 - 870; J. M. ESTEBAN ET AL.: 'New method for the chelation of Indium-111 to monoclonal antibodies: Biodistribution and imaging of athymic mice bearing human colon carcinoma xenografts.'
 - CHEMICAL ABSTRACTS, vol. 107, no. 24, 14 December 1987, Columbus, Ohio, US; abstract no. 232314, A. LOCKSHIN ET AL.: 'Improved tumor localization of Indium-111-labeled monoclonal antibody with chelator administration to host nude mice.' page 404 ;column 2 ;
 - CHEMICAL ABSTRACTS, Vol. 108, issued 1987, HNATOWICH et al., "DTPA-coupled proteins-procedures and precautions", Abstract No. 108851r, Nucl. Med. 14(6), 563-8 (1987).
 - CHEMICAL ABSTRACTS, Vol. 100, issued 1984, GANSOW et al., "Monoclonal antibodies conjugated with a metal chelate for cancer treatment", Abstract No. 126881q Fr. Demande 2,527,928 issued 07 June 1982.
 - Subramanian R. et al.: "Bifunctional chelating agents for radiometal-labeled monoclonal antibodies", in CANCER IMAGING WITH RADIOLABELED ANTIBODIES, Goldenberg D.M. (ed.), 1990, Kluwer Academic Publishers, pp 183-199

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 0 495 878 B1

Description

FIELD OF INVENTION

The invention relates to the labeling of biomolecules with a labeling reagent selected from In or Y. More specifically, the invention relates to the separation of labeled biomolecules from unbound labeling reagent following the labeling reaction. The invention has particular relevance when the biomolecule is a protein and the labeling reagent is a radionuclide. Particular applications lie in the fields of immunodiagnosics and immunotherapy.

BACKGROUND OF THE INVENTION

Biomolecules can be labeled with any of a variety of reagents, including radionuclides, toxins, vitamins, fluorescent compounds and chelating agents. A labeling reagent may be incorporated as a constituent of a biomolecule, for example by metabolic labeling or by nick translation, or may be attached to a biomolecule by a covalent bond or another intermolecular force. Examples of the latter category of labeling method include the use of isothiocyanate derivatives of fluorochromes to render antibodies fluorescent, the use of photoactive derivatives of biotin to label nucleic acids and the use of oxidative or enzyme-mediated reactions to attach iodine onto proteins at tyrosine residues. The labeling procedure can be as simple as mixing a biomolecule and a labeling reagent.

United States Patent No. 4,707,352 discloses a labeling method which comprises the step of contacting an unlabeled compound, consisting of a chelating agent conjugated to a biomolecule, with an ion transfer material to which is bound a radiometal. The affinity of said ion transfer material for the radiometal is less than the affinity of said chelating agent for said metal. In the example a column containing an ion exchange resin loaded with ^{63}Ni is used. A chelator conjugate is passed through the column and eluted as the radiolabeled chelator conjugate. The components to perform the labeling method may be incorporated into kits.

U.S. Patent No. 4, 652, 440 discloses a method for producing stable technetium- or rhenium-labelled antibodies by using a molar excess of free or carrier-bound diethylene triaminepentaacetic acid (DTPA) in order to inhibit technetium or rhenium binding to non-stable binding sites of the antibody.

At the conclusion of a labeling reaction, it is often desirable to purify the labeled biomolecule, the product, by separating any reactant, particularly unreacted labeling reagent, from said product. Presence of unbound labeling reagent can confound outcomes by associating with irrelevant molecules (non-specific binding) or by contributing to the background.

Because many labeling reagents are small molecules or elements, common methods for separating product from unbound reagent rely on size or weight dif-

ferential. Thus, size exclusion chromatography or dialysis may be used. If there is a charge difference between the product and reactant, ion exchange chromatography is a suitable separation method.

A method for purifying radiolabeled antibody combining ion exchange and size exclusion resins is disclosed in U.S. Patent No. 4,454,106. A 9 cm column is made comprising 1 ml of an ion retarding resin above 1 ml of a 200-400 mesh cation exchange resin above 7 ml of gel filtration medium capable of fractionating particles 1,500-25,000 daltons in weight. The column is equilibrated with a buffer consisting of 200 mM sodium chloride and 10 mM MES at pH 6.0. In the related U.S. Patent No. 4,472,509, the preferred bed for purifying technetium-labeled antibodies is the three component bed described above modified to include 1 ml of an anion exchange resin situated below the cation exchange resin and above the gel filtration medium.

Mukkala et al. (Anal Biochem (1989) 176:319-325) labeled IgG with Eu^{3+} using bridging chelators. The labeled antibody product was purified from the reactants by passing the reaction mixture over a combined 1.5 x 5 cm Sephadex G-50 (Pharmacia Fine Chemicals; dextran beads) column and a 1.5 x 30 cm Trisacryl GF2000 (Reactifs IBF; polyacrylamide beads) column.

Esteban et al. (J. Nucl Med (1987) 28:861-870) compared four protocols for purifying ^{111}In -labeled antibody at completion of the labeling procedure. They divided a single labeling preparation into four equal portions. One aliquot was treated with excess EDTA in solution without subsequent separation. Another aliquot was passed over a 1 x 8 cm gel exclusion (Sephadex G-50 fine) column. The third aliquot was injected onto a 7.5 mm x 30 cm HPLC (TSK 3000) column and the final aliquot was treated sequentially over the G50 column and then the TSK 3000 column. The poorest results were obtained with the EDTA treatment, the G-50 column was marginally better, the HPLC-purified labeled antibody had a tumor:liver ratio three times that of the EDTA-purified aliquot and the best results were obtained with the G-50/TSK 3000 combination. The authors concluded that the widely used EDTA method was inefficient in producing clean preparations and other purification methods should be considered if one wants to minimize background.

United States Patent No. 4,775,638 discloses a single vial technique for radiolabeling antibody. The method comprises introducing radioisotope into a sealed vessel in which the inner surface of said vessel is coated with a catalyst; introducing antibody into said vessel; incubating the mixture; introducing into said vessel an ion exchange resin which absorbs radioisotope not bound to antibody; withdrawing the mixture; and separating the resin from the supernatant. The preferred resin is an anion exchanger such as AG 1-X8 (Bio-Rad). Although the method is directed primarily to radio-iodination procedures, the inventor surmised that the catalyst-mediated attachment of radioisotope to antibody and the subsequent purification of said labeled

antibody might be adapted for ^{67}Ga and ^{111}In labeling by chelation.

Notwithstanding the variety of separation methods available to the artisan, a systematic limitation constrains the use of labeled biomolecules in procedures demanding high sensitivity. That limitation is the sometimes low efficacy of removing unbound labeling reagent of many current methods in the art. A clear example is the use of radiolabeled anti-cancer antibodies *in situ* for the detection of malignant growths, a method known as radioimmunoscintigraphy. For various reasons not related directly to the instant invention, often, only a small amount of antibody binds to a malignancy. Thus, the signal is difficult to discern even under ideal conditions. It is not uncommon for diagnosis to be rendered impossible because of high background. Accordingly, one way to assure or enhance detection is using labeled antibody that is significantly free of unbound radionuclides.

A further limitation to the use of gel exclusion chromatography is the propensity of IgM antibodies to bind nonspecifically and at times irreversibly to the column matrix. See for example Halpern et al., *J. Nucl. Med.* (1988) 29:1688-1696.

Another limitation relates to the prolonged time frame of most procedures. Many of the radionuclides and particularly the radiometals have a short half-life, which if not days, often is a matter of hours. Thus rapid purification enhances the specific activity of a labeled biomolecule preparation.

Furthermore, the separation procedures recited above are not without additional shortcomings. Many require costly equipment and skilled technicians, are prone to biologic contamination, require close monitoring, are not amenable to scale-up and the like. The equipment may be difficult and costly to decontaminate in the event of radioactive spills.

Resolution of the above-noted problems provided the motivation for the instant invention. Disclosed herein is a means for obtaining a higher degree of separation of labeled product from unbound reactant than that achieved using current procedures. The instant method is advantageous for several reasons, including simplicity and inexpensiveness. Additionally the method is not prone to biologic contamination, does not affect the bioactivity of the biomolecule, offers high concentrated yields, can be used in a standard hospital laboratory by nursing staff, is easy to dispose of after use, has a long shelf life and is adaptable for use with a variety of labeling reagents and biomolecules.

SUMMARY OF THE INVENTION

The instant invention relates to a method for separating after a labeling reaction labeled biomolecules, the product, from any unbound or weakly bound in or Y which are the labeling reagent. The invention teaches the use of chelator attached matrices to scavenge said unbound labeling reagent. The method offers several

advantages, including simplicity, highly efficient removal of unbound labeling reagent and economy. The reagents to carry out the invention are readily adaptable into kit form for use in applied settings, as in hospitals and nuclear pharmacies.

BRIEF DESCRIPTION OF THE DRAWING

Figure 1 depicts the use of a plurality of vessels to carry out the invention.

Figure 2 depicts another embodiment comprising a single vessel with a plurality of compartments.

Figure 3 depicts a method for making chelator attached matrix.

Figure 4 depicts an alternative method for preparing chelator attached matrix.

DETAILED DESCRIPTION OF THE INVENTION

All of the terms used in the specification and the claims are known to one with ordinary skill in the art. Nevertheless, to provide clear and consistent understanding of the specification and claims, including the scope given to such terms, the following definitions are provided:

Biomolecule: Element or compound compatible in or with a biologic entity.

Bound: Physical attachment of labeling reagent to a biomolecule.

Chelator: Reagent that binds metal ions with high affinity. Known also as chelating agent.

Conjugate: A composite. As a verb, to join.

Derivatize: Modify a parent substance.

Labeling reagent: In or Y to be reacted with a biomolecule that confers an additional property on said biomolecule wherein said biomolecule can be detected, tracked or monitored.

Polyaminopolycarboxylate: Compound, used often as a chelating agent, characterized by a plurality of amino groups and a plurality of carboxyl groups.

Product: The resulting substance of a reaction between or among reactants.

Reactant: Ingredient of a reaction, for example, a biomolecule is mixed with a labeling reagent to produce a conjugate, said biomolecule and said labeling reagent are two reactants of that reaction, and said conjugate is the product.

Unbound Reactant: Reactant that is not physically attached to another substance.

The invention turns on the use of chelator or chelating polymer conjugated to an inert matrix, preferably a particulate matrix, to scavenge unbound labeling reagent. The chelating agent is selected to have high avidity and high affinity for lower molecular weight compounds of which many labeling reagents are. Suitable chelating agents include ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA), poly-azamacrocyclics, benzyl DTPA, benzyl EDTA, LiLo, IDAC, other activated derivatives of polyaminopolycarboxylates, some antibiotics, crown ethers, other macrocyclic compounds, natural chelating proteins such as transferrin, apoferritin and metallothionein, and diazotized aromatic amines. Chelating polymer and other multi-functional chelators may prove even more effective than those mentioned above.

Suitable matrices include glass, polystyrene, amine derivatized polymers, silica, agarose, silica propylamine, copolymers and other resins. With certain matrix-chelator combinations, the attachment of the chelating agent to the matrix does not require a complex reaction. Polystyrene and glass for example, have an inherent binding capacity for small molecules, proteins and the like. However in the case of amine derivatized polymer beads or amine derivatized polymer-coated glass beads, the chelators can be linked chemically to the beads.

Chelators can be synthesized on a matrix. By way of example, amine derivatized beads, available commercially, are packed into a column. The beads are coupled to iminodiacetate groups by simple carboxymethylation and the column is flushed with buffer. The beads are treated with ammonia, the column flushed and then again subjected to the carboxymethylation step. The process is repeated until the desired number of carboxylate groups are obtained.

The invention is suitable particularly for procedures that require biomolecules labeled with metals selected from In or Y. It is not uncommon for the biomolecules to be labeled using a chelating agent bridge, i.e., the chelating agent is conjugated to the biomolecule, and the conjugate is then loaded with a metal wherein the metal is bound by the chelating agent. Suitable metals include ^{88}Y , ^{90}Y , and ^{111}In , although it is preferable when using a chelator that the species be a cation.

A particular advantage is realized when the same species of chelating agent is conjugated both to the biomolecule and to the matrix. Because of no difference in affinity, there is little chance that the separation process will remove labeling reagent once bound to the biomolecule. To assist in visualizing some of the combinations in which chelators are conjugated to matrix and biomolecule, consider the following formulae:

BM-A-L

M-B-L

wherein BM is a biomolecule;
M is a matrix;
A is a first chelator;
B is a second chelator; and
L is a label.

With K representing binding affinity, several comparisons can be symbolized in the following manner:

$$A = B \quad (1)$$

$$A \neq B \text{ and } K_A = K_B \quad (2)$$

$$K_A > K_B \quad (3)$$

$$K_A < K_B \quad (4)$$

In another embodiment of the scavenging procedure, three chelators are used with the additional component designated as:

M-C-L

wherein C is a third chelator, and BM-A-L, M-B-L and M-C-L are used simultaneously in the procedure. Chelators B and C either are both conjugated to the same matrix or are each conjugated to a separate matrix. Comparisons relating to the latter embodiment include:

$$A = B \text{ and } K_C < K_A \quad (5)$$

$$K_B < K_A \text{ and } K_C < K_A \quad (6)$$

$$K_B = K_A \text{ and } K_C < K_A \quad (7)$$

As mentioned hereinabove, comparison (1) wherein the same chelator is conjugated to the biomolecule and to the matrix is a preferred combination. Comparison (2) is equivalent functionally to comparison (1). The efficiency of purification represented by comparison (3) depends on how much lower K_B is from K_A . Apparent deficiencies may be remedied with increasing amounts of M-B-L. Comparison (4) is acceptable if K_A is not much less than K_B . Comparisons (5), (6) and (7) may provide unexpected benefits with certain chelators.

The labeling procedure can be performed in one or more sealed reaction vessels or in a multiple-chambered single reaction vessel. Figure 1 diagrams an embodiment requiring multiple vessels, comprising, a first reaction vial, a second vial containing chelator attached matrix and a third product vial. Radiolabeling occurs in the first vial, the reaction mixture is removed to the second vial wherein said mixture contacts the chelator-matrix conjugate, thereafter the supernatant is removed, for example by means of a syringe, and said supernatant, which may be filtered, is collected in the third vial.

Figure 2 illustrates another embodiment in which a single vessel with multiple compartments is repre-

sented. Said compartments are separated from each other by means for permitting transfer of reaction mixture from a first compartment (I) to a second adjacent compartment (II) containing chelator attached matrix. In this embodiment a valve device, e.g. a stopcock, separates the compartments. Equivalents of the stopcock include rupturable non-permeable membranes, moveable stoppers and scored glass. The third compartment (III) which receives the reaction mixture after the unbound labeling reagent is removed from the reaction mixture by the chelator-matrix conjugate, may be attached to said second compartment.

A third embodiment uses a sealed two compartment vessel. The labeling reaction is conducted in the first compartment, into which the reactants are introduced, for example, by a syringe. The second compartment contains a chelator-matrix. After the labeling reaction is complete, a stopper means separating the first compartment and the second compartment is breached and the reactants are contacted with the chelator-matrix in the second compartment. After sufficient time for unbound label to be captured by the chelator-matrix, the labeled biomolecule in the supernatant may be removed using a syringe. Because the entire procedure takes place in a sealed, sterile vessel, the supernatant may be administered directly to a patient. The size of the matrix bound to the chelator, e.g. polymer beads, would be selected to be too large to enter the syringe.

Appropriate matrices are selected and conjugated with a chelating agent. Figure 3 is an example of preparing beads by indirect coupling. Human serum albumin (HSA) and diethylenetriaminepentaacetate (DTPA) are conjugated. The HSA-DTPA conjugate is attached to a particulate polymer matrix (P) to form P-HSA-DTPA. In another reaction vial, a chelator (CHL), in this example preferably DTPA, is conjugated to a monoclonal antibody (MoAb). The MoAb-CHL conjugate is labeled with indium ($\text{In}(111)$). In the figure unbound labeling reagent is denoted as $\text{In}(III)$ and labeled antibody as MoAb-CHL- $\text{In}(111)$. P-HSA-DTPA is added to the reaction mixture to scavenge $\text{In}(111)$ by chelation.

Figure 4 is another embodiment wherein beads and chelator are coupled directly. Alkylamine derivatized particulate polymer matrix ($\text{P-NH} \cdot \cdot \cdot$) is conjugated with DTPA to form AM-DTPA. In a fashion similar to that depicted in Figure 3, AM-DTPA scavenges $\text{In}(111)$ from the reaction mixture.

To further minimize non-specific binding to the matrix, the conjugates can be exposed to a proteinaceous or carbohydrate material to block those non-specific sites. Suitable blocking agents include bovine serum albumin, human serum albumin, sera, polyvinylpyrrolidone, dextran and ficoll. The chelator-matrix conjugates are washed thoroughly and an appropriate quantity is charged into a first vessel or into a chamber of said multiple-chambered vessel.

The biomolecule is conjugated with a chelating agent, preferably the same species as that conjugated

to the matrix. Following the conjugation step, the biomolecule is separated from the unconjugated chelating agent by, for example, precipitation or gel exclusion chromatography. The resulting solution is charged into a second vessel or into a separate chamber of said multiple-chambered vessel. The labeling reagent, which generally is purchased from commercial vendors, is then introduced into the biomolecule-containing solution and chelation allowed to proceed under appropriate incubation conditions. In the next step, the labeling reaction solution is removed to the vessel or chamber containing the chelator-matrix conjugate. The final mixture is incubated with periodic mixing. The supernatant containing the labeled biomolecule is removed.

Alternatively, the biomolecule which serves as the effector molecule, for example, the antibody or nucleic acid probe, need not be labeled with an agent that in itself is detectable. Instead, said effector molecule is labeled with a first binding partner molecule and the detectable labeling agent is conjugated to a second binding partner molecule, wherein said first and second binding partner molecules react with each other to form a conjugate. That alternative labeling method is known as pretargeting. For example, tissue-reacted streptavidin-conjugated antibody may be visualized using radiolabeled biotin and a hybridized nucleic acid probe containing a poly-A tail may be visualized with an alkaline phosphatase conjugated poly-T oligonucleotide and appropriate phosphatase substrate such as NBT/BCIP. In the first antibody example, streptavidin and biotin are the first and second binding partner molecules and in the second nucleic acid example, poly-A and poly-T polynucleotides are the first and second binding partner molecules. Polymers that may be used as binding partner molecules include poly-N-vinylpyrrolidone, polyvinyl alcohols, polyethylene oxide and poly-N-vinylpyridine which reacts with polyacrylic acids and polymethacrylic acids.

The following non-limiting examples further illustrate and show aspects of the instant invention.

EXAMPLE 1

Polystyrene beads were conjugated with DTPA in a two-step method. Human serum albumin (HSA) in 50 mM phosphate-buffered saline, pH 7.2 was incubated with a 100-fold molar excess of DTPA dianhydride at room temperature for 15 minutes. Unconjugated DTPA was removed by passing the mixture over a G-50 column.

The HSA-DTPA solution was adjusted to 14 mg/ml and about 40 quarter inch, spherical, non-porous beads were added to the solution. The mixture was incubated with gentle shaking at room temperature for 2 hours. The liquid was decanted, the beads washed with distilled water and dried under vacuum.

EXAMPLE 2

A 0.1 mg/ml solution of DTPA anhydride in dry chloroform was prepared and an aliquot containing the desired quantity of DTPA was added to a reaction vessel. The chloroform was removed by evaporation with nitrogen gas at room temperature. A pH 7.0 solution of antibody (approximately 0.5 mg) in 0.05 M bicarbonate buffer was added to said reaction vessel to produce a 7:1 molar ratio of anhydride to protein. The solution was incubated with shaking for one minute and the coupled antibody was recovered by passage over a Sephadex G-50 column.

EXAMPLE 3

The radionuclide was made 0.5 M in acetate, using 1.0 M acetate, with a final pH of 6.0. The radionuclide solution was added to the antibody-DTPA conjugate along with 0.1 ml of 25% human serum albumin and the mixture was incubated for 5-30 minutes with frequent stirring.

EXAMPLE 4

HSA-DTPA beads were added to a solution containing ^{111}In in acetate/citrate buffer in a total volume of 0.75 ml for about 30 minutes. The solution was removed and the radioactivity bound to the beads was determined.

Number of Beads	Radioactivity in μCi
5	22
12	30
20	62

There is a direct correlation between the number of beads and the amount of bound radioactivity. Also, washing the beads with 1 M HCl removed all bound radioactivity, enabling the beads to be reused.

EXAMPLE 5

HSA-DTPA was labeled with ^{111}In in citrate/acetate buffer as described above. An aliquot was removed and treated with excess DTPA. Said DTPA-treated aliquot was analyzed by thin layer chromatography to determine percent free ^{111}In . The aliquot contained 12.2% free ^{111}In . Five HSA-DTPA beads were added to the HSA-DTPA- ^{111}In solution and the mixture was incubated at room temperature for 30 minutes. An aliquot was removed from that mixture, treated with excess DTPA and analyzed by TLC for free ^{111}In . Said second aliquot contained 3.9% free ^{111}In .

EXAMPLE 6

LiLo is a novel chelator developed at OTC/Bionetics Research Institute and is described in WO 90/14881. The chelator was attached to amine derivatized (AM) beads by exposing 60 AM beads to 5 ml of a saturated solution of LiLo prepared in water or in phosphate-buffered saline, pH 7.2. The pH of the mixture was adjusted to 7.5-8.5 using NaOH. The solution was stirred overnight at room temperature. The liquid was decanted and 1 M HCl was added to the beads. The mixture was incubated at room temperature for 10 minutes. That step removes free metal bound to LiLo-conjugated AM beads. The beads were rinsed repeatedly with 0.1 M HCl. That was followed by distilled water rinses until the wash was neutral to pH paper. The beads were dried under vacuum and stored in a dessicator.

EXAMPLE 7

Two hundred microcuries of indium chloride was combined in an acid-washed reaction vial with 15 μl of acetate buffer (0.6 M, pH 5.5) and 15 μl of citrate buffer (0.06 M, pH 5.5). Antibody-DTPA conjugate (157 μg in phosphate-buffered saline, pH 7.2) was added to the solution and the mixture was incubated at room temperature for about 30 minutes. Then, about 1 ml of phosphate-buffered saline (0.05 M, pH 7.2) was added. An aliquot of the reaction mixture was treated with excess DTPA solution to determine the percentage of unbound Indium-111 in the reaction mixture. To the remaining reaction solution, eight AM-LiLo beads were added. After incubating with the beads for about 30 minutes, an aliquot of the reaction solution was treated with excess DTPA. A chromatographic analysis was carried out to determine the percentage of unbound Indium-111 with the following results:

Method	Percent of Indium-111 bound to the antibody
Before Beads	83.0 %
After Beads (AM-LiLo)	99.7 %

EXAMPLE 8

IDAC-2 is a novel chelator developed at OTC/BRI and described in WO 90/14881. IDAC-2 was conjugated to AM beads according to the method described in Example 7.

Although the foregoing disclosure describes the instant invention in detail by way of illustration for purposes of enablement and preferred embodiments, one having ordinary skill in the art will know that changes, modifications and other uses can be made, and are

available, without departing from the scope and spirit of the invention. The scope of the invention is, therefore, indicated by the appended claims and any change that comes within the meaning and range of equivalency of the claims are to be embraced within the scope.

Claims

1. A method for scavenging unbound In or Y from a reaction mixture for labelling biomolecules comprising biomolecules bound through chelators to In or Y and unbound In or Y, comprising the step of adding to the reaction mixture an insoluble chelator-matrix conjugate capable of binding unbound In or Y after the binding of In or Y to biomolecules is essentially complete, and binding unbound In or Y to the chelator-matrix, wherein said biomolecule is selected from the group consisting of peptide, protein, nucleic acid, oligonucleotide and polynucleotide
2. The method of claim 1 wherein said biomolecule is a protein and said protein is an immunoglobulin or an immunoglobulin fragment.
3. The method of claim 1 wherein said In or Y is a radio-nuclide.
4. The method of claim 1 wherein said chelator is a polyaminopolycarboxylate or a cyclopolyazacarboxylate.
5. The method of claim 1 wherein said chelator is a biomolecule.
6. The method of claim 1 wherein said matrix is particulate.
7. The method of claim 1 wherein said matrix is derivatized.
8. The method of claim 1 wherein said matrix comprises the inside surface of a vessel.
9. The method of claim 1 wherein said matrix is a membrane.
10. A kit, comprising a sterile vessel containing a chelator-matrix conjugate for performing the method of claim 1.
11. The kit of claim 10, further comprising a second vessel containing a chelator-immunoglobulin conjugate.
12. The kit of claim 10 wherein the vessel has a plurality of chambers and said chelator-matrix conjugate is in one chamber and a chelator-immunoglobulin conjugate is in a second chamber.
13. A method for preparing a biomolecule composition labeled with In or Y essentially free of unbound In or Y comprising the steps of:
 - (a) contacting a biomolecule comprising a chelating moiety and In or Y in a reaction mixture and permitting the In or Y to bind to the biomolecule; and
 - (b) contacting the mixture of step (a) with [a] an insoluble chelator-matrix conjugate capable of binding unbound In or Y in an amount sufficient to bind essentially all unbound In or Y, whereby a solid phase containing bound In or Y and a liquid phase containing labeled biomolecules are produced, wherein said biomolecule is selected from the group consisting of peptide, protein, nucleic acid, oligonucleotide and polynucleotide.
14. The method of claim 13 wherein said biomolecule is an immunoglobulin.
15. The method of claim 13 wherein the In or Y is radioactive.
16. The method of claim 13 wherein said chelator-matrix conjugate comprises a polyaminopolycarboxylate attached to a particulate.
17. The method of claim 13 wherein the liquid phase containing labeled biomolecules is separated from the solid phase by means of a syringe.
18. The method of claim 13 wherein steps (a) and (b) are carried out in separate reaction vessels and the reagents are introduced and withdrawn with a syringe.
19. The method of claim 13 wherein steps (a) and (b) are carried out in separate compartments of a single vessel and said compartments are interconnected by a means permitting transfer of contents between compartments.
20. The method of claim 19 which further comprises a third compartment which is connected to said second compartment, wherein said second and third compartments are interconnected by a means for permitting transfer of contents between compartments.
21. The method of claim 19 wherein the means permitting transfer of contents between compartments is blocked by a removable blocking means.

Patentansprüche

1. Verfahren zum Auffangen von ungebundenem In oder Y aus einem Reaktionsgemisch zum Markie-

- ren von Biomolekülen, welches durch Chelatoren an In oder Y gebundene Biomoleküle und ungebundenes In oder Y umfasst, das den Schritte der Zugabe eines unlöslichen Chelator-Matrix-Konjugats zum Reaktionsgemisch umfasst, welches in der Lage ist, ungebundenes In oder Y zu binden, nachdem die Bindung von In oder Y an die Biomoleküle im wesentlichen vollständig ist, sowie das Binden von ungebundenem In oder Y an die Chelator-Matrix, worin dieses Biomolekül aus der Gruppe ausgewählt wird, die von Peptid, Protein, Nukleinsäure, Oligonucleotid und Polynucleotid gebildet wird.
2. Verfahren nach Anspruch 1, worin dieses Biomolekül ein Protein und dieses Protein ein Immunglobulin oder ein Immunglobulinfragment ist.
 3. Verfahren nach Anspruch 1, worin dieses In oder Y ein Radionuklid ist.
 4. Verfahren nach Anspruch 1, worin dieser Chelator ein Polyaminpolycarboxylat oder ein Cyclopolyazacarboxylat ist.
 5. Verfahren nach Anspruch 1, worin dieser Chelator ein Biomolekül ist.
 6. Verfahren nach Anspruch 1, worin diese Matrix aus Partikeln besteht.
 7. Verfahren nach Anspruch 1, worin diese Matrix derivatisiert ist.
 8. Verfahren nach Anspruch 1, worin diese Matrix die innenseitige Oberfläche eines Gefässes umfasst.
 9. Verfahren nach Anspruch 1, worin diese Matrix eine Membran ist.
 10. Set, das ein steriles Gefäss umfasst, welches ein Chelator-Matrix-Konjugat enthält, um das Verfahren gemäss Anspruch 1 auszuführen.
 11. Set nach Anspruch 10, das weiter ein zweites Gefäss umfasst, welches ein Chelator-Immunglobulin-Konjugat enthält.
 12. Set nach Anspruch 10, worin das Gefäss eine Mehrzahl von Kammern aufweist und sich dieses Chelator-Matrix-Konjugat in einer Kammer und ein Chelator-Immunglobulin-Konjugat in einer zweiten Kammer befindet.
 13. Verfahren zum Herstellen einer Biomolekülzusammensetzung, die mit In oder Y markiert und im wesentlichen frei von ungebundenem In oder Y ist, das folgende Schritte umfasst:
 - (a) In Kontakt bringen eines Biomoleküls, das einen chelierenden Teil umfasst, mit In oder Y in einem Reaktionsgemisch und Zulassen, dass sich das In oder Y an das Biomolekül bindet; und
 - (b) In Kontakt bringen des Gemischs des Schritts (a) mit [a] einem unlöslichen Chelator-Matrix-Konjugat, das in der Lage ist, In oder Y in einer Menge zu binden, die ausreichend ist, um im wesentlichen alles ungebundene In oder Y zu binden, wodurch eine Festphase, die gebundenes In oder Y enthält, und eine Flüssigphase, die markierte Biomoleküle enthält, hergestellt werden, worin dieses Biomolekül aus der Gruppe ausgewählt wird, die von Peptid, Protein, Nukleinsäure, Oligonucleotid und Polynucleotid gebildet wird.
 14. Verfahren nach Anspruch 13, worin dieses Biomolekül ein Immunglobulin ist.
 15. Verfahren nach Anspruch 13, worin das In oder das Y radioaktiv ist.
 16. Verfahren nach Anspruch 13, worin dieses Chelator-Matrix-Konjugat ein an einem Partikel befestigtes Polyaminpolycarboxylat umfasst.
 17. Verfahren nach Anspruch 13, worin die Flüssigphase, welche die markierten Biomoleküle enthält, mittels einer Spritze von der Festphase getrennt wird.
 18. Verfahren nach Anspruch 13, worin die Schritte (a) und (b) in separaten Reaktionsgefässen ausgeführt und die Reagenzien mit einer Spritze eingeführt und entnommen werden.
 19. Verfahren nach Anspruch 13, worin die Schritte (a) und (b) in separaten Abteilen eines einzigen Gefässes ausgeführt werden und diese Abteile durch ein Mittel miteinander verbunden sind, welches den Inhaltsaustausch zwischen den Abteilen ermöglicht.
 20. Verfahren nach Anspruch 19, das weiter ein drittes Abteil umfasst, das mit diesem zweiten Abteil verbunden ist, worin dieses zweite und dritte Abteil durch ein Mittel miteinander verbunden sind, welches den Inhaltsaustausch zwischen den Abteilen ermöglicht.
 21. Verfahren nach Anspruch 19, worin das Mittel, das den Inhaltsaustausch zwischen den Abteilen ermöglicht, durch ein entfernbares Blockiermittel blockiert wird.

Revendications

1. Un procédé d'élimination d'In ou Y non lié d'un mélange réactionnel de marquage de biomolécules comprenant des biomolécules liées par l'intermédiaire de chélatants à In ou Y et non liées à In ou Y, comprenant les étapes d'addition au mélange réactionnel d'un conjugué insoluble chélatant-matrice susceptible de fixer In ou Y après que la fixation de In ou Y aux biomolécules est pratiquement complète, et la fixation du In ou Y non lié au chélatant-matrice, dans lequel ladite biomolécule est choisie dans le groupe consistant en peptide, protéine, acide nucléique, oligonucléotide et polynucléotide.
2. Le procédé selon la revendication 1, dans lequel ladite biomolécule est une protéine et ladite protéine est une immunoglobuline ou un fragment d'immunoglobuline.
3. Le procédé selon la revendication 1, dans lequel ledit In ou Y est un radionucléide.
4. Le procédé selon la revendication 1, dans lequel ledit chélatant est un polyaminopolycarboxylate ou un cyclopolyazcarboxylate.
5. Le procédé selon la revendication 1, dans lequel ledit chélatant est une biomolécule.
6. Le procédé selon la revendication 1, dans lequel ladite matrice est particulière.
7. Le procédé selon la revendication 1, dans lequel ladite matrice est dérivée.
8. Le procédé selon la revendication 1, dans lequel ladite matrice comprend la surface interne d'un récipient.
9. Le procédé selon la revendication 1, dans lequel ladite matrice est une membrane.
10. Un kit, comprenant un récipient stérile contenant un conjugué chélatant-matrice pour mettre en oeuvre le procédé selon la revendication 1.
11. Le kit selon la revendication 10, comprenant en outre un second récipient contenant un conjugué chélatant-immunoglobuline.
12. Le kit selon la revendication 10, dans lequel le récipient comporte une pluralité de chambres et ledit conjugué chélatant-matrice se trouve dans l'une des chambres et le conjugué chélatant-immunoglobuline est dans une seconde chambre.
13. Une méthode de préparation d'une composition de biomolécule marquée par In ou Y pratiquement

débarassée de In ou Y non lié comprenant les étapes de:

- (a) mise en contact d'une biomolécule comprenant la partie chélatante et In ou Y dans un mélange réactionnel et permet de laisser In ou Y se fixer à la biomolécule;
- (b) mise au contact du mélange de l'étape (a) avec un conjugué insoluble chélatant-matrice susceptible de fixer In ou Y non lié en une quantité suffisante pour lier pratiquement la totalité de In ou Y non lié, ce qui permet d'obtenir une phase solide contenant In ou Y lié et une phase liquide contenant les biomolécules marquées, dans lequel ladite biomolécule est choisie dans le groupe consistant en peptide, protéine, acide nucléique, oligonucléotide et polynucléotide.

14. Le procédé selon la revendication 13, dans lequel ladite biomolécule est une immunoglobuline.
15. Le procédé selon la revendication 13, dans lequel le In ou le Y est radioactif.
16. Le procédé selon la revendication 13, dans lequel ledit conjugué chélatant-matrice est un polyaminopolycarboxylate fixé à une substance particulaire.
17. Le procédé selon la revendication 13, dans lequel la phase liquide contenant des biomolécules marquées est séparées de la phase solide à l'aide d'une seringue.
18. Le procédé selon la revendication 13, dans lequel les étapes (a) et (b) sont effectuées dans des récipients réactionnels séparés et les réacteurs sont introduits et prélevés à l'aide d'une seringue.
19. Le procédé selon la revendication 13, dans lequel on effectue les étapes (a) et (b) dans des compartiments séparés d'un récipient unique et dans lequel lesdits compartiments sont reliés entre eux par des moyens permettant le transfert des contenus entre compartiments.
20. Le procédé selon la revendication 19 qui comprend en outre un troisième compartiment qui est relié audit second compartiment, lesdits second et troisième compartiments étant reliés entre eux par des moyens permettant le transfert des contenus entre les compartiments.
21. Le procédé selon la revendication 19, dans lequel des moyens permettant le transfert des contenus entre compartiments est bloqué par des moyens de blocage amovibles.





FIG. 1

FIG. 2











FIG. 3





FIG. 4

